Endpoint failure signals
Failed endpoint clinical trial signals: how I would search them
A failed endpoint is one of the cleaner signals in clinical trial failure analysis, but it still needs context. The useful workflow is to find the source language, then verify what the trial actually measured.
- The current database contains 1,427 stopped records with endpoint, efficacy, futility, or weak-benefit language.
- 1,358 of those records are terminated, 49 are withdrawn, and 20 are suspended.
- Oncology is the largest disease area in this slice with 422 records.
- Endpoint failure language can mean lack of efficacy, futility, no treatment effect, missed endpoints, or insufficient benefit.
- The classification is a screening signal and should be verified against the original NCT record.
The short version
When people search for a failed endpoint clinical trial, they are usually looking for something more specific than a terminated trial. They want to know whether the study missed an endpoint, stopped for futility, showed weak efficacy, or failed to show enough benefit to continue.
That is why this slice matters. It is narrower than all stopped trials and closer to the question people actually care about: did the clinical evidence support the intervention in that setting?
Why endpoint language is useful
Endpoint-related stop language is useful because it tends to sit closer to the scientific result than broad administrative language. Phrases like lack of efficacy, futility, failed to meet endpoint, no survival benefit, or insufficient treatment effect are stronger signals than a status field alone.
Still, I would not treat one sentence in a registry record as the final answer. Endpoint design, statistical assumptions, interim-analysis rules, patient selection, and the comparator all affect what the stop reason actually means.
How I would use the database
I would start with endpoint and futility language, then filter by disease area, phase, sponsor, and intervention. After that, I would open the NCT record and look for the primary endpoint, enrollment size, status history, and any sponsor disclosure or publication.
This is especially useful when you want to understand whether a mechanism struggled repeatedly, whether a sponsor has repeated weak-efficacy stops, or whether one disease area is unusually hard for a modality.
What not to do
Do not turn every endpoint-related stop into a simple failed drug label. A Phase 2 futility stop in one population may still leave room for another dose, biomarker group, combination, or endpoint strategy.
The better wording is usually more precise: endpoint failure signal, futility signal, weak-efficacy signal, or stopped trial with endpoint-related source language.
Endpoint-related stopped records
| Dataset signal | Current records |
|---|---|
| Endpoint, efficacy, or futility signals | 1,427 |
| Terminated | 1,358 |
| Withdrawn | 49 |
| Suspended | 20 |
Largest disease areas
| Disease area | Records |
|---|---|
| Oncology | 422 |
| Other | 320 |
| Neurology | 109 |
| Infectious Disease | 108 |
| Gastroenterology & Hepatology | 104 |
| Cardiovascular | 68 |
Largest sponsor counts
| Sponsor | Records |
|---|---|
| Eli Lilly and Company | 43 |
| Novartis Pharmaceuticals | 42 |
| Pfizer | 36 |
| GlaxoSmithKline | 32 |
| Janssen Research & Development, LLC | 23 |
| Hoffmann-La Roche | 22 |
Continue from here
FAQ
Is a failed endpoint the same as a failed clinical trial?
Not always. A failed endpoint is a strong evidence signal, but the interpretation depends on endpoint design, patient population, phase, comparator, and source documentation.
What phrases should I search for?
Useful terms include lack of efficacy, futility, failed endpoint, failed to meet endpoint, insufficient benefit, no treatment effect, and no survival benefit.
Where should I verify the result?
Start with the NCT record, then check protocol details, endpoints, publications, sponsor disclosures, and regulatory documents where available.
Source note: counts are generated from the current ClinicalTrials.gov-derived stopped-trial dataset used by ClinicalTrialFailures.com. These labels are analytical screening signals, not medical advice.